INNPF Stock Chart & Stats
$1.56
-$0.06(-2.45%)
At close: 4:00 PM EDT
$1.56
-$0.06(-2.45%)
Day’s Range― - ―
52-Week Range$1.43 - $14.90
Previous CloseN/A
Volume200.00
Average Volume (3M)61.00
Market Cap
$7.96M
Enterprise Value$8.16
Total Cash (Recent Filing)$6.68M
Total Debt (Recent Filing)$1.42M
Price to Earnings (P/E)―
Beta-0.68
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding4,498,772
10 Day Avg. Volume20
30 Day Avg. Volume61
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA very high gross margin indicates strong unit economics in the current product portfolio. If sustained as revenue scales, it could provide substantial operating leverage once research, development, and commercial expenses are better absorbed.
Moderate LeverageModerate leverage and a meaningful equity base provide financial flexibility relative to a highly indebted peer. This gives InnoCan more capacity to fund development and operations, although continued losses could gradually reduce that buffer.
Proprietary Delivery PlatformsProprietary cannabinoid formulations and long-acting delivery approaches could differentiate InnoCan beyond commodity products. Successful platform development may support recurring licensing, product, or partnership opportunities across human and animal-health applications.
Bears Say
Revenue ContractionThe return to TTM revenue contraction suggests that earlier expansion has not yet translated into a consistently compounding commercial base. Persistent weakness would limit operating leverage and make it harder to absorb the company’s fixed research and commercial costs.
Unproven ProfitabilityStrong gross margins have not yet converted into operating or net profits, indicating that expenses continue to absorb most gross profit. Until profitability becomes durable, InnoCan remains dependent on revenue improvement, cost discipline, or additional financing.
Negative Cash GenerationRenewed operating and free-cash-flow deficits show that current losses are translating into cash burn rather than being offset by working capital. Continued negative cash generation could consume the balance-sheet cushion and increase future funding requirements.
InnoCan Pharma News
INNPF FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was $1.43 and its highest was $14.90 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is $7.96M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Dec 02, 2026 which is in 89 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on Aug 31, 2026. The company reported -$0.007 earnings per share for the quarter.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -$0.007 in its last earnings report. Following the earnings report the stock price went down -12.684%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in INNPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InnoCan Pharma
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Voyageur Pharmaceuticals
―
Avicanna
―
Ownership Overview
0.88%
Insiders
―
Mutual Funds
― Other Institutional Investors
99.12% Public Companies and
Individual Investors